Physician profile
Aida A Morse
NPI 1548498645
$1,707.40
in general payments reported to CMS, 2019-2025
26 companies · $479 in 2025
The $479 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $179 · 2023: $514 · 2024: $536 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521 · Education: $7.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.74 |
| Education | $7.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $404.41 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $186.51 | 2022-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.15 | 2022-2024 | Ofev, Spiriva Respimat, Combivent Respimat |
| Genzyme Corporation | $97.49 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $68.82 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $67.60 | 2023-2025 | Mounjaro, Zepbound |
| Amgen INC. | $65.12 | 2022-2025 | Tezspire |
| Pfizer INC. | $60.97 | 2024-2025 | |
| Mylan Specialty L.P. | $55.11 | 2023-2024 | Yupelri |
| Dexcom, INC. | $49.13 | 2023-2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $48.90 | 2024-2025 | Voquezna |
| Inogen, INC. | $48.12 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Harmony Biosciences LLC | $47.14 | 2023-2024 | Wakix |
| Novo Nordisk INC | $46.31 | 2025 | Ozempic, Wegovy |
| Exact Sciences Corporation | $38.51 | 2023 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $35.62 | 2023 | |
| Merck Sharp & Dohme LLC | $31.02 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $24.71 | 2022 | |
| Grifols USA, LLC | $24.11 | 2024 | Prolastin-C Liquid |
| Daiichi Sankyo INC. | $22.76 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.18 | 2024 | Xifaxan, Trulance |
| Medtronic, INC. | $20.75 | 2023 | Venaseal |
| Verona Pharma, INC. | $20.60 | 2025 | Ohtuvayre |
| Dynavax Technologies Corporation | $19.77 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.51 | 2022 | |
| Philips North America LLC | $14.08 | 2025 | Vest Therapy Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aida Morse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.